Application of ceramide hydrolase ACER2 in preparation of medicine for improving beta cell function and preventing and / or treating diabetes

By targeting the ceramide hydrolase ACER2 of vascular endothelial cells and overexpressing or using its extracellular vesicles, the problem of insufficient β-cell function recovery in existing technologies has been solved, achieving the effectiveness and safety of β-cell regeneration and diabetes treatment.

CN122104651APending Publication Date: 2026-05-29TIANJIN MEDICAL UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202411737347.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-29
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Existing diabetes treatments cannot effectively restore β-cell function, leading to irreversible pathological progression. They also have side effects and compliance issues, and cannot effectively control the progression of diabetes.

Method used

Targeting the ceramide hydrolase ACER2 in vascular endothelial cells, through overexpression or overexpression agents such as extracellular vesicles, improves β-cell function, including promoting β-cell regeneration, reducing damage and apoptosis, lowering blood glucose, increasing insulin levels and β-cell numbers, and increasing S1P levels.

Benefits of technology

It significantly improves β-cell function, lowers blood glucose, enhances glucose tolerance in diabetic mice, increases the number of β-cells, reduces ceramide accumulation, alleviates inflammation, and reduces the risk of complications.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides application of ceramide hydrolase ACER2 in preparation of drugs for improving beta cell functions and preventing and / or treating diabetes. According to the application, the metabolic enzyme ACER2 of vascular endothelial cells is specifically knocked out through a pancreatic beta cell injury regeneration model and a diabetic mouse model for the first time, and the indispensable effect of ACER2 on regulating the ceramide level and improving the function of beta cells and the pathological phenotype of diabetes is proved; the extracellular vesicle overexpressing ACER2 is constructed, and it is proved that the extracellular vesicle overexpressing ACER2 has a certain application prospect in the aspects of pancreas islet beta cell function improvement and diabetes treatment.
Need to check novelty before this filing date? Find Prior Art